104 lines (103 with data), 3.6 kB

T1	Age 2 13	41-year-old
T2	Sex 14 17	man
T3	Sign_symptom 23 34	weight loss
E1	Sign_symptom:T3 
T4	Sign_symptom 36 42	nausea
E2	Sign_symptom:T4 
T5	Sign_symptom 44 52	vomiting
E3	Sign_symptom:T5 
T6	Sign_symptom 68 72	pain
E4	Sign_symptom:T6 
T7	Biological_structure 58 67	abdominal
R1	MODIFY Arg1:T7 Arg2:E4	
T8	Clinical_event 77 85	referred
E5	Clinical_event:T8 
T9	Diagnostic_procedure 103 110	CT scan
E6	Diagnostic_procedure:T9 
T10	Biological_structure 93 102	abdominal
R2	MODIFY Arg1:T10 Arg2:E6	
T11	Disease_disorder 123 147	intraabdominal pathology
E7	Disease_disorder:T11 
A1	POLARITY E7 UNCERTAIN
T12	Diagnostic_procedure 161 163	CT
E8	Diagnostic_procedure:T12 
T13	Biological_structure 171 178	abdomen
R3	MODIFY Arg1:T13 Arg2:E8	
T14	Nonbiological_location 200 211	institution
R4	MODIFY Arg1:T14 Arg2:E8	
T15	Detailed_description 229 259	standard venous phase protocol
R5	MODIFY Arg1:T15 Arg2:E8	
T16	Diagnostic_procedure 284 306	positive oral contrast
E9	Diagnostic_procedure:T16 
R6	SUB_PROCEDURE Arg1:E9 Arg2:E8	
T17	Medication 317 342	barium sulfate suspension
E10	Medication:T17 
T18	Dosage 343 351	2.1% w/v
R7	MODIFY Arg1:T18 Arg2:E10	
T19	Detailed_description 353 365	Mallinckrodt
R8	MODIFY Arg1:T19 Arg2:E10	
R9	SUB_PROCEDURE Arg1:E10 Arg2:E9	
T20	Medication 394 403	iopromide
E11	Medication:T20 
R10	SUB_PROCEDURE Arg1:E11 Arg2:E9	
T21	Dosage 384 390	125 ml
T22	Dosage 405 416	300 mg I/mL
T23	Detailed_description 418 445	Ultravist, Bayer HealthCare
R11	MODIFY Arg1:T23 Arg2:E11	
R12	MODIFY Arg1:T21 Arg2:E11	
R13	MODIFY Arg1:T22 Arg2:E11	
T24	Administration 271 280	ingestion
R14	MODIFY Arg1:T24 Arg2:E10	
T25	Administration 371 380	injection
R15	MODIFY Arg1:T25 Arg2:E11	
T26	Coreference 456 458	CT
E12	Coreference:T26 
T27	Detailed_description 448 455	helical
R16	MODIFY Arg1:T27 Arg2:E12	
R17	IDENTICAL Arg1:E12 Arg2:E8	
T28	Detailed_description 479 489	65-s delay
R18	MODIFY Arg1:T28 Arg2:E12	
T29	Detailed_description 499 533	64-slice GE Lightspeed VCT scanner
R19	MODIFY Arg1:T29 Arg2:E12	
T30	Detailed_description 535 568	GE Medical Systems; Milwaukee, WI
R20	MODIFY Arg1:T30 Arg2:T29	
T31	Diagnostic_procedure 571 585	Axial sections
E13	Diagnostic_procedure:T31 
R21	SUB_PROCEDURE Arg1:E13 Arg2:E12	
T32	Biological_structure 593 600	abdomen
R22	MODIFY Arg1:T32 Arg2:E13	
T33	Sign_symptom 660 664	mass
E14	Sign_symptom:T33 
T34	Lab_value 610 615	large
T35	Volume 617 628	18×22×22 cm
R23	MODIFY Arg1:T35 Arg2:E14	
R24	MODIFY Arg1:T34 Arg2:E14	
T36	Detailed_description 630 643	heterogeneous
T37	Biological_structure 644 659	retroperitoneal
R25	MODIFY Arg1:T37 Arg2:E14	
R26	MODIFY Arg1:T36 Arg2:E14	
T38	Biological_structure 691 709	left adrenal gland
R27	MODIFY Arg1:T38 Arg2:E14	
T39	Detailed_description 721 754	multiple areas of macroscopic fat
R28	MODIFY Arg1:T39 Arg2:E14	
T40	History 780 852	no documented clinical or laboratory evidence of adrenal hormonal excess
T41	Therapeutic_procedure 930 948	surgical resection
E15	Therapeutic_procedure:T41 
T42	Sign_symptom 969 973	mass
E16	Sign_symptom:T42 
T43	Biological_structure 956 968	left adrenal
R29	MODIFY Arg1:T43 Arg2:E16	
T44	Disease_disorder 1042 1066	adrenocortical carcinoma
E17	Disease_disorder:T44 
T45	Severity 1032 1041	low-grade
R30	MODIFY Arg1:T45 Arg2:E17	
T46	Diagnostic_procedure 994 1016	pathologic examination
E18	Diagnostic_procedure:T46 
*	OVERLAP E1 E2 E3 E4
R31	BEFORE Arg1:E4 Arg2:E5	
*	OVERLAP E5 E6 E7 E8 E12 E13 E14
R32	BEFORE Arg1:E14 Arg2:E15	
*	OVERLAP E15 E16
R33	MODIFY Arg1:E16 Arg2:E15	
R34	BEFORE Arg1:E16 Arg2:E18	
*	OVERLAP E18 E17